Early Investigation of Glucose Monitoring After Gestational Diabetes Pilot

Study acronym: ENGAGED
StatusRecruiting
PhaseNot specified
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 12 months later May 30, 2026 → May 30, 2027
See other at-risk trials from Ohio State University

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion pushed from May 30, 2026 to May 30, 2027
    • Eligibility criteria expanded, about 11 words
    • Secondary endpoints: details revised at 1 of 3 entries
  2. Re-verified, no change to tracked fieldsv7
  3. Primary completion date: Sep 30, 2025 to May 30, 2026
    • Start date: Oct 1, 2024 to Jun 6, 2025
    • Study completion date: Sep 30, 2026 to May 30, 2027
    • Collaborators expanded, about 2 words
    v6
  4. Trial status: Not Yet Recruiting to Recruiting
    • Primary completion date: Apr 30, 2025 to Sep 30, 2025
    • Study completion date: Apr 30, 2026 to Sep 30, 2026
    • Interventions: Dexcom G6/G7 CGM (Device), Hemoglobin A1c (Diagnostic Test), Oral Glucose Tolerance Test (Diagnostic Test) to Continuous glucose monitor (Device), Hemoglobin A1c (Diagnostic Test), Oral Glucose Tolerance Test (Diagnostic Test)
    v5
  5. Start date: Jun 1, 2024 to Oct 1, 2024
    • Primary completion date: Dec 30, 2024 to Apr 30, 2025
    • Study completion date: Dec 1, 2025 to Apr 30, 2026
    v4
Show 2 earlier versionsHide 2 earlier versions
  1. Study description expanded, about 1 wordv3
  2. Primary completion date: Jun 30, 2024 to Dec 30, 2024v2 Show 5 more changesShow less
    • Start date: Jan 1, 2024 to Jun 1, 2024
    • Study completion date: Sep 1, 2025 to Dec 1, 2025
    • Interventions: Dexcom G7 CGM (Device), Hemoglobin A1c (Diagnostic Test), Oral Glucose Tolerance Test (Diagnostic Test) to Dexcom G6/G7 CGM (Device), Hemoglobin A1c (Diagnostic Test), Oral Glucose Tolerance Test (Diagnostic Test)
    • Study description shortened, about 53 words
    • Eligibility criteria shortened, about 4 words
  1. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Ohio State University
254 trials monitored
See 18 trials at risk
Diabetes
5,101 trials monitored
See 233 trials at risk
One third of women with gestational diabetes (GDM), diabetes diagnosed during pregnancy, have abnormal glucose levels within 3 years after pregnancy, but follow up is low. Continuous glucose monitors (CGM), a small sensor inserted under the skin, may be able to screen women with GDM for diabetes risk. The investigators will ask postpartum women to use CGM at 6-8 weeks postpartum and answer surveys about quality of life after wearing the CGM. The investigators will collect data on blood glucose trends for future studies if participants find CGM use acceptable. The investigators hope to learn if CGM could improve postpartum follow up experiences for people with recent GDM.
Trial Details
NCT Number NCT06184373
Lead Sponsor Ohio State University
Collaborators: DexCom, Inc.
Conditions
(from sponsor)		 Gestational Diabetes, Hyperglycemia
Related terms Diabetes, Gestational, Hyperglycemia
Enrollment 20 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov